Symptoms of Huntington's disease appear late in life. Research reveals how DNA repeats grow toxic over time, explaining the ...

Subtle signs of neurodegeneration can be detected in blood, CSF, and neuroimaging, up to 20 years before the motor symptoms ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company"). Atalanta, a biotechnology company based in ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

The weekly number of lab-confirmed influenza cases on Long Island was the highest in at least the past two seasons, with ...

Huntington's disease kills a population of cells called ... When large numbers of these cells die, patients develop involuntary movements in the arms, legs, and face, and many patients also ...